miR ‐33a inhibits cell growth in renal cancer by downregulation of MDM4 expression

ConclusionTaken together, our study indicates thatmiR ‐33a inhibits RCC cell growth by targetingMDM4.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research

Related Links:

Authors: Cui XF, Cui XG, Leng N Abstract Papillary renal cell carcinoma (PRCC) accounts for about 10 percent of all renal cell carcinomas, and the prognosis is poor for people with advanced disease. Interleukin-20 receptor subunit beta (IL20RB) is a single-pass type I membrane protein of the type II cytokine receptor family and is related to the pathogenesis of chronic inflammation and autoimmune diseases, including psoriasis, glaucoma, vitiligo, rheumatoid arthritis, and inflammatory bowel disease. However, little has been reported on IL20RB with respect to cancer, especially in PRCC. Thus, we performed this study...
Source: Journal of Toxicologic Pathology - Category: Toxicology Tags: J Toxicol Pathol Source Type: research
SummaryThe treatment landscape of metastatic renal cell cancer (mRCC) is rapidly evolving. To date in 2019 twelve drugs are licensed for this indication, two more drugs are awaited to be introduced into our portfolio of treatment options by the end of the year. First-line treatment has robust clinical trial data and is clearly stated by the consensus guidelines. It consists either of a  tyrosine kinase inhibitor (TKI) monotherapy for favorable risk patients—defined by the Heng or IMDC (International mRCC Database Consortium) score—or the immuno-oncology (IO) combination of ipilimumab and nivolumab (Ipi/Niv...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 11 November 2019Source: Pathology - Research and PracticeAuthor(s): Heejin Bang, Soomin Ahn, Eun Ji Kim, Seung Tae Kim, Ha Young Park, Jeeyun Lee, Kyoung-Mee KimABSTRACTRapamycin-insensitive companion of mTOR (RICTOR) is a key component of mammalian target of rapamycin (mTOR) complex 2 (mTORC2), and promotes cellular proliferation and survival through the activation of downstream AGC kinase family members. The amplification of RICTOR has been proposed as a therapeutically relevant genomic alteration. However, other than next-generation sequencing, precise diagnostic methods to detect RICT...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Certain cytokines synergize in activating anti-cancer immunity at the site of disease and it may be desirable to generate biopharmaceutical agents, capable of simultaneous delivery of cytokine pairs to the tumor. In this article, we have described the cloning, expression and characterization of IL2-XE114-TNFmut, a dual-cytokine biopharmaceutical featuring the sequential fusion of interleukin-2 (IL2) with the XE114 antibody in scFv format and a tumor necrosis factor mutant (TNFmut). The fusion protein recognized the cognate antigen (carbonic anhydrase IX, a marker of hypoxia and of renal cell carcinoma) with high affinity a...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
RAS protein activator like 2 (RASAL2) belongs to the RAS GTPase-activating protein family and plays an important role in several cancers, including ovarian cancer, nasopharyngeal carcinoma, malignant astrocytoma, renal cell carcinoma, bladder cancer, colorectal cancer, liver cancer, triple-negative breast cancer, lung adenocarcinoma, and pancreatic ductal adenocarcinoma. Traditionally, RASAL2 has been regarded as a tumor suppressor but recent studies have found that it is an oncogene in specific types of cancer, such as colorectal cancer, liver cancer, triple-negative breast cancer, triple-negative/estrogen receptor-negati...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
SUMMARY: The use of transoral sonography–guided fine-needle aspiration for intraoperative localization of retropharyngeal masses has been described by Fornage et al. The purpose of this study was to assess the accuracy of this technique. We reviewed the images and medical records of 26 patients with a retropharyngeal lesion suspicious for a metastatic lymph node of Rouviere identified on CT and/or PET/CT. There were 14 patients with a history of thyroid cancer, 7 with mucosal squamous cell carcinoma, 1 with renal cell carcinoma, 1 with parotid acinic cell cancer, 1 with metastatic colon adenocarcinoma, and 2 with no ...
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: HEAD & amp; NECK Source Type: research
AbstractCabozantinib treatment prolonged progression‐free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characterist...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Genitourinary Cancer Brief Communications Source Type: research
ConclusionWe report for the first time the significant downregulation of UCN3 in RCC. These results demonstrate a possible involvement of the CRH system and its significance in carcinogenesis of RCC.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: The use of NSAIDs was not related to acute kidney injury, postsurgical complications, or prolonged hospital stay in patients with renal cancer undergoing nephrectomy. PMID: 31715614 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
ConclusionsUnmarried men are at higher risk of not benefiting of cytoreductive nephrectomy, metastasectomy, or systemic therapy than their married counterparts. Unmarried women are at higher risk of not benefiting of cytoreductive nephrectomy or systemic therapy. These gender-related differences cumulate in higher CSM in unmarried men, but not in unmarried women.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Kidney Cancer | Renal Cell Carcinoma | Study